Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease

The antifibrotic therapies nintedanib and pirfenidone were first approved by the United States for the treatment of idiopathic pulmonary fibrosis in 2014. In 2020, nintedanib received U.S. Food and Drug Administration (FDA) approval for the treatment of all progressive fibrosing interstitial lung di...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilfong, Erin M., Aggarwal, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Interstitial Lung Disease in Autoimmune Rheumatic Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669869/
https://www.ncbi.nlm.nih.gov/pubmed/34917177
http://dx.doi.org/10.1177/1759720X211060907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669869/
https://www.ncbi.nlm.nih.gov/pubmed/34917177
http://dx.doi.org/10.1177/1759720X211060907

Ejemplares similares